Categories: News

LANZAJET ANNOUNCES SELECTION OF FLUOR CORPORATION FOR FRONT-END ENGINEERING AND DESIGN (FEED) FOR PROJECT SPEEDBIRD – LANZAJET’S FLAGSHIP UK SAF PLANT

CHICAGO, Nov. 4, 2025 /PRNewswire/ — LanzaJet, Inc., a leading next-gen fuels technology company and producer of sustainable fuels, has recently awarded the Front-End Engineering and Design (FEED) for Project Speedbird to Fluor Corporation (NYSE: FLR). 

- Advertisement -

Developed with support from British Airways, LanzaJet’s Project Speedbird is a commercial scale ethanol-to-SAF facility to be located in Teesside, UK, which will produce over 90,000 tonnes (30 million gallons) of SAF and renewable diesel annually, reducing British Airways’ CO₂ emissions by approximately 230,000 tonnes per year—equivalent to 26,000 British Airways domestic flights.

- Advertisement -

“Project Speedbird is the next commercial scale facility in our portfolio that LanzaJet is developing, working closely with British Airways. It is an important step in the continued scale-up of our leading sustainable fuels technology,” said Jimmy Samartzis, CEO of LanzaJet. “Partnering with the globally recognized engineering, procurement, and construction (EPC) company Fluor Corporation shows our commitment to the highest standards in project execution.”

- Advertisement -

The project is expected to bring significant opportunities for the North East region and create hundreds of jobs through construction to operation, was recently awarded £10 million ($13 million) by the U.K. Government through its Advanced Fuels Fund.

- Advertisement -

“Project Speedbird marks a pivotal advancement in the global effort to decarbonize aviation,” said Mike Alexander, Group President, Project Execution, Fluor Corporation “By accelerating the adoption of sustainable fuel technologies, this project will help redefine the future of flight. Fluor is proud to bring our engineering and design expertise to this visionary initiative.”

- Advertisement -

Project Speedbird is set to transform the aviation sector by producing SAF from low-carbon ethanol using LanzaJet’s patented and fully integrated Alcohol-to-Jet (ATJ) technology solution. The LanzaJet ATJ solution is deployed at commercial scale at LanzaJet’s Freedom Pines Fuels facility in Georgia, USA.

- Advertisement -

About LanzaJet

LanzaJet is a leading alternative fuels technology provider with patented ethanol-based alcohol-to-jet (ATJ) technology. LanzaJet is impacting economic development, energy security, decarbonization, and national security by accelerating the production and deployment of Sustainable Aviation Fuel (SAF) and other alternative fuels. LanzaJet is supported by investors and funders including Airbus, ANA, Breakthrough Energy, British Airways, Groupe ADP, Microsoft, Mitsui, MUFG, LanzaTech, Shell, Southwest Airlines, Suncor, the US Department of Energy, and the UK Department for Transport. Last year, LanzaJet was named a TIME100 Most Influential Company, a Rising Star Company of the Year by S&P Global, and one of MIT’s 15 Climate Tech Companies to Watch in 2024. Further information is available at: https://www.lanzajet.com/

- Advertisement -

Logo – https://mma.prnewswire.com/media/2709678/lanzajet_logo_black_Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/lanzajet-announces-selection-of-fluor-corporation-for-front-end-engineering-and-design-feed-for-project-speedbird–lanzajets-flagship-uk-saf-plant-302603611.html

- Advertisement -

Recent Posts

Deepak Group Goes Beyond Green with hands-On Mangrove Restoration

Deepak Group undertakes mangrove plantation drive on World Environment DaySustainable restoration along the Paniyadra coast,…

2 hours ago

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction,…

6 hours ago

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as…

6 hours ago

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)…

6 hours ago

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

June 05, 2026 20:13 ET  | Source: Bluejay Diagnostics, Inc. $8.5 million upfront with up…

6 hours ago